Media stories about Tetraphase Pharmaceuticals (NASDAQ:TTPH) have trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tetraphase Pharmaceuticals earned a news impact score of 0.07 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.1228695630823 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Tetraphase Pharmaceuticals’ (TTPH) “Buy” Rating Reiterated at Stifel Nicolaus (americanbankingnews.com)
- $1.46 Million in Sales Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter (americanbankingnews.com)
- Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections (finance.yahoo.com)
- Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per Share (americanbankingnews.com)
- Jacques Dumas Sells 7155 Shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock (topactu.net)
Several research firms recently weighed in on TTPH. Stifel Nicolaus restated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research downgraded shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, August 30th. Piper Jaffray Companies began coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 price target for the company. Finally, BidaskClub upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals has an average rating of “Hold” and an average price target of $10.88.
Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down 0.58% during mid-day trading on Tuesday, reaching $6.88. 740,601 shares of the company’s stock were exchanged. Tetraphase Pharmaceuticals has a 1-year low of $3.11 and a 1-year high of $9.93. The stock’s market capitalization is $351.24 million. The firm’s 50-day moving average is $6.33 and its 200 day moving average is $7.26.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.07). Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The business had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $1.54 million. During the same period last year, the company earned ($0.47) EPS. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. Analysts forecast that Tetraphase Pharmaceuticals will post ($2.54) earnings per share for the current fiscal year.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the sale, the insider now owns 17,500 shares of the company’s stock, valued at $105,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Tetraphase Pharmaceuticals (TTPH) Earning Somewhat Favorable Media Coverage, Report Shows” was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.tickerreport.com/banking-finance/2887268/tetraphase-pharmaceuticals-ttph-earning-somewhat-favorable-media-coverage-report-shows.html.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.